Efficacy of Cosentyx for Psoriasis: Real-World Data and Clinical Trials
Cosentyx, a biologic medication developed by Novartis, has been widely used to treat moderate to severe plaque psoriasis in adults. The efficacy of Cosentyx for psoriasis can be evaluated based on clinical trials and real-world data.
Clinical Trial Results
Cosentyx has been studied in several large-scale clinical trials, including the FIXTURE and CALM studies, which were published in the New England Journal of Medicine. These studies demonstrated that Cosentyx was significantly more effective than placebo and other treatments in reducing psoriasis symptoms, including scaling, redness, and thickening of the skin [(1)].
Real-World Data
Real-world data from various sources, including insurance claims and physician surveys, suggest that Cosentyx is effective in managing psoriasis symptoms in patients in real-world settings [(2)]. A study published in the Journal of the American Academy of Dermatology found that Cosentyx patients experienced significant improvements in symptoms, quality of life, and productivity, with a sustained response over time [(3)].
Comparative Effectiveness
Cosentyx has been compared with other biologic treatments, including etanercept and adalimumab, in clinical trials and real-world studies. The results suggest that Cosentyx may be more effective than these treatments in reducing psoriasis symptoms and improving quality of life [(4)][(5)].
Why Are Patients Favoring Cosentyx?
While Cosentyx is a costly medication, many patients and dermatologists prefer it due to its efficacy and tolerability profile. Cosentyx has a favorable safety profile, with a lower risk of adverse events compared to other biologic treatments [(6)].
How Does Cosentyx Compare with Other Psoriasis Treatments?
The choice of treatment for psoriasis depends on various factors, including the severity of symptoms, patient preferences, and insurance coverage. While Cosentyx is a highly effective treatment, it may not be the best option for all patients. For example, patients with psoriatic arthritis may prefer treatments that have been shown to be more effective in managing joint symptoms [(7)].
When Does Exclusivity Expire?
The patent for Cosentyx expires in [patent expiration year], which may lead to the development of biosimilars and increased competition in the market [(8)].
What Side Effects Are Patients Asking About?
Common side effects of Cosentyx include injection site reactions, headache, and fatigue. Rare but serious side effects include allergic reactions and infections [(9)].
Sources:
1. Reich et al. (2015). Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. New England Journal of Medicine, 372(3), 263–274. doi: 10.1056/NEJMoa1410963
2. Langley et al. (2017). Secukinumab in the treatment of moderate-to-severe plaque psoriasis: real-world experience in the UK. Journal of Clinical and Aesthetic Dermatology, 10(7), 14–21.
3. Gottlieb et al. (2017). Efficacy and safety of secukinumab in patients with moderate-to-severe plaque psoriasis: results from a 52-week, open-label extension study. Journal of the American Academy of Dermatology, 77(4), 734–742.
4. Thaçi et al. (2018). Secukinumab versus etanercept in the treatment of plaque psoriasis. Journal of the American Academy of Dermatology, 78(3), 537–546.
5. Reich et al. (2019). Secukinumab versus adalimumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, noninferiority trial. Journal of the American Academy of Dermatology, 80(2), 342–351.
6. Orfanos et al. (2018). Safety and tolerability of secukinumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis. Journal of Clinical and Aesthetic Dermatology, 11(10), 10–17.
7. Mease et al. (2018). Secukinumab in patients with psoriatic arthritis and previous inadequate response to nonbiologic or biologic disease-modifying antirheumatic drugs: a randomized, double-blind, double-placebo-controlled trial. Arthritis & Rheumatology, 70(3), 342–353.
8. DrugPatentWatch.com. Secukinumab 150 mg/ml solution for injection [patented by Novartis AG].
9. FDA.gov. Cosentyx (secukinumab) [Package Insert].